Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NAD+ at Home is a specialized healthcare and wellness company that provides Nicotinamide Adenine Dinucleotide (NAD+) therapy for self-administration. The company offers pharmaceutical-grade NAD+ through subcutaneous injection kits and IV protocols, designed to support mitochondrial health, DNA repair, and cellular energy production. Their business model utilizes a telehealth platform where medical professionals consult with clients before shipping treatment kits directly to their homes. By focusing on the longevity and anti-aging markets, NAD+ at Home aims to improve cognitive function and metabolic health for individuals seeking convenient alternatives to in-clinic infusions. The company's services are positioned at the intersection of personalized medicine and consumer wellness.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NAD+ at Home.